Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Abstract Background Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. Methods In this study, human osteosarcoma cell lines were...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-04-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13046-019-1147-6 |
| _version_ | 1830489231897657344 |
|---|---|
| author | Yitian Wang Wei Yu Jian Zhu Junjie Wang Kaishun Xia Chengzhen Liang Huimin Tao |
| author_facet | Yitian Wang Wei Yu Jian Zhu Junjie Wang Kaishun Xia Chengzhen Liang Huimin Tao |
| author_sort | Yitian Wang |
| collection | DOAJ |
| description | Abstract Background Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. Methods In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies against CD166 was performed on different cell samples. CD166-specific T cells were obtained by viral gene transfer of corresponding DNA plasmids and selectively expanded using IL-2 and IL-15. The ability of CD166.BBζ CAR-T cells to kill CD166+ osteosarcoma cells was evaluated in vitro and in vivo. Results CD166 was selectively expressed on four different human osteosarcoma cell lines, indicating its role as the novel target for CAR-T cell therapy. CD166.BBζ CAR-T cells killed osteosarcoma cell lines in vitro; the cytotoxicity correlated with the level of CD166 expression on the tumor cells. Intravenous injection of CD166.BBζ CAR-T cells into mice resulted in the regression of the tumor with no obvious toxicity. Conclusions Together, the data suggest that CD166.BBζ CAR-T cells may serve as a new therapeutic strategy in the future clinical practice for the treatment of osteosarcoma. |
| first_indexed | 2024-12-21T19:33:56Z |
| format | Article |
| id | doaj.art-faaa0a37fb5a433daa3b30bea9db4cb2 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-12-21T19:33:56Z |
| publishDate | 2019-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-faaa0a37fb5a433daa3b30bea9db4cb22022-12-21T18:52:39ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-04-0138111110.1186/s13046-019-1147-6Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcomaYitian Wang0Wei Yu1Jian Zhu2Junjie Wang3Kaishun Xia4Chengzhen Liang5Huimin Tao6Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityDepartment of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang UniversityAbstract Background Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. Methods In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies against CD166 was performed on different cell samples. CD166-specific T cells were obtained by viral gene transfer of corresponding DNA plasmids and selectively expanded using IL-2 and IL-15. The ability of CD166.BBζ CAR-T cells to kill CD166+ osteosarcoma cells was evaluated in vitro and in vivo. Results CD166 was selectively expressed on four different human osteosarcoma cell lines, indicating its role as the novel target for CAR-T cell therapy. CD166.BBζ CAR-T cells killed osteosarcoma cell lines in vitro; the cytotoxicity correlated with the level of CD166 expression on the tumor cells. Intravenous injection of CD166.BBζ CAR-T cells into mice resulted in the regression of the tumor with no obvious toxicity. Conclusions Together, the data suggest that CD166.BBζ CAR-T cells may serve as a new therapeutic strategy in the future clinical practice for the treatment of osteosarcoma.http://link.springer.com/article/10.1186/s13046-019-1147-6CAR-TCD1664-1BBOsteosarcomaImmunotherapy |
| spellingShingle | Yitian Wang Wei Yu Jian Zhu Junjie Wang Kaishun Xia Chengzhen Liang Huimin Tao Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma Journal of Experimental & Clinical Cancer Research CAR-T CD166 4-1BB Osteosarcoma Immunotherapy |
| title | Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma |
| title_full | Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma |
| title_fullStr | Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma |
| title_full_unstemmed | Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma |
| title_short | Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma |
| title_sort | anti cd166 4 1bb chimeric antigen receptor t cell therapy for the treatment of osteosarcoma |
| topic | CAR-T CD166 4-1BB Osteosarcoma Immunotherapy |
| url | http://link.springer.com/article/10.1186/s13046-019-1147-6 |
| work_keys_str_mv | AT yitianwang anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT weiyu anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT jianzhu anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT junjiewang anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT kaishunxia anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT chengzhenliang anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma AT huimintao anticd16641bbchimericantigenreceptortcelltherapyforthetreatmentofosteosarcoma |